NTRK1 and chordoma: A participant with chordoma and outlier high immune signature T-cell scores, but low TMB, achieved PR to single agent ICI therapy (LOE5) and an additional patient with a TRK fusion achieved PR to TRK inhibitor therapy (LOE4B at the time of MTB).